Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
How do you choose roflumilast vs ensifentrine in COPD patients with dyspnea despite adequate LABA + LAMA (+ ICS therapy where indicated)?
2025 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD
Related Questions
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
Is methacholine challenge on its way out?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Have you observed adverse mental health side effects in patients who start montelukast?
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
